Zobrazeno 1 - 10
of 279
pro vyhledávání: '"Joaquín, Arribas"'
Autor:
Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D. Staniszewska, Joanna Domènech-Vivó, Eduardo García-Galea, Alejandro Moles-Fernández, Flaminia Pedretti, Heura Domènech, Olga Rodríguez, Marta Guzmán, Enrique J. Arenas, Helena Verdaguer, Fernando J. Calero-Nieto, Sara Talbot, Luis Tobalina, Elisabetta Leo, Alan Lau, Paolo Nuciforo, Rodrigo Dienstmann, Teresa Macarulla, Joaquín Arribas, Orland Díez, Sara Gutiérrez-Enríquez, Josep V. Forment, Mark J. O’Connor, Mark Albertella, Judith Balmaña, Violeta Serra
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-17 (2024)
Abstract Background Poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors (PARPi) are targeted therapies approved for homologous recombination repair (HRR)-deficient breast, ovarian, pancreatic, and prostate cancers. Since inhibition of PARP1 is
Externí odkaz:
https://doaj.org/article/68b3f150f248467b98d10c77d2ec9d7a
Autor:
Irene Manzanares-Sierra, Marta Lalinde, Carla Ramon-Duaso, Júlia Pinho, Joaquín Arribas, Arnau Busquets Garcia
Publikováno v:
IBRO Neuroscience Reports, Vol 15, Iss , Pp S445- (2023)
Externí odkaz:
https://doaj.org/article/9bdc8579e06746ef8acb55ce05d20f87
Autor:
Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández, Faye Su, Kui Lin, Robert B. Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C. Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S. Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-20 (2022)
CDK4/6 inhibitor resistance is common in breast cancer. Here, the authors show that p16 overexpression may be linked to reduced efficacy of CDK4/6 inhibition, and show that the combination with PI3K inhibitors may increase anti-tumour effects.
Externí odkaz:
https://doaj.org/article/c3a330e420d34dc992aab0ec2b80986a
Autor:
Manuel Gámez-Chiachio, Ángela Molina-Crespo, Carmen Ramos-Nebot, Jeannette Martinez-Val, Lidia Martinez, Katja Gassner, Francisco J. Llobet, Mario Soriano, Alberto Hernandez, Marco Cordani, Cristina Bernadó-Morales, Eva Diaz, Alejandro Rojo-Sebastian, Juan Carlos Triviño, Laura Sanchez, Ruth Rodríguez-Barrueco, Joaquín Arribas, David Llobet-Navás, David Sarrió, Gema Moreno-Bueno
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-19 (2022)
Abstract Background Gasdermin B (GSDMB) over-expression promotes poor prognosis and aggressive behavior in HER2 breast cancer by increasing resistance to therapy. Decoding the molecular mechanism of GSDMB-mediated drug resistance is crucial to identi
Externí odkaz:
https://doaj.org/article/f27d67a436224cd7aff26d109a24a883
Autor:
Ángela Quintana, Enrique Javier Arenas, Cristina Bernadó, José Fernández Navarro, Jonatan González, Anna Esteve-Codina, Teresa Moliné, Merce Marti, Giuseppe Curigliano, Peter Schmid, Vicente Peg, Joaquín Arribas, Javier Cortés
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionTumor infiltrating lymphocytes (TILs) are known to be a prognostic and predictive biomarker in breast cancer, particularly in triple negative breast cancer (TNBC) patients. International guidelines have been proposed to evaluate them in t
Externí odkaz:
https://doaj.org/article/b12b9107a3c848078a4ede6efaf4d2df
Autor:
Alison E. Smith, Emanuela Ferraro, Anton Safonov, Cristina Bernado Morales, Enrique J. Arenas Lahuerta, Qing Li, Amanda Kulick, Dara Ross, David B. Solit, Elisa de Stanchina, Jorge Reis-Filho, Neal Rosen, Joaquín Arribas, Pedram Razavi, Sarat Chandarlapaty
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Resistance to HER2 inhibition in HER2- amplified breast cancer is common in the metastatic setting and the underlying molecular mechanisms remain unknown. Here, the authors, perform genomic profiling of 733 HER2-amplified breast cancers and propose g
Externí odkaz:
https://doaj.org/article/0069fe3f63d440449928bce36543115c
Publikováno v:
STAR Protocols, Vol 3, Iss 4, Pp 101712- (2022)
Summary: Immunotherapy has revolutionized cancer treatment, but preclinical models are required to understand immunotherapy resistance mechanisms underlying patient relapse. This protocol describes how to generate an acquired resistance humanized in
Externí odkaz:
https://doaj.org/article/f19ba5ec1a944e3091ffab279a2b13b9
Autor:
Enrique J. Arenas, Alex Martínez-Sabadell, Irene Rius Ruiz, Macarena Román Alonso, Marta Escorihuela, Antonio Luque, Carlos Alberto Fajardo, Alena Gros, Christian Klein, Joaquín Arribas
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Several mechanisms of resistance to T cell-engaging therapies have been described for solid tumors. Here, by using T cell bispecific antibodies and chimeric antigen receptors (CAR) T cells targeting HER2, the authors show that cancer cell intrinsic d
Externí odkaz:
https://doaj.org/article/aa94e03a034246f68048ebc589ddfa65
Publikováno v:
Cancers, Vol 15, Iss 4, p 1069 (2023)
Breast cancer is the leading cause of cancer-related deaths among women worldwide. HER2-positive breast cancer, which represents 15–20% of all cases, is characterized by the overexpression of the HER2 receptor. Despite the variety of treatments ava
Externí odkaz:
https://doaj.org/article/9a5958d42b434e6b8fd998f1c6bb8960
Autor:
César Serrano, Ana Vivancos, Antonio López-Pousa, Judit Matito, Francesco M. Mancuso, Claudia Valverde, Sergi Quiroga, Stefania Landolfi, Sandra Castro, Cristina Dopazo, Ana Sebio, Anna C. Virgili, María M. Menso, Javier Martín-Broto, Miriam Sansó, Alfonso García-Valverde, Jordi Rosell, Jonathan A. Fletcher, Suzanne George, Joan Carles, Joaquín Arribas
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations af
Externí odkaz:
https://doaj.org/article/9f289e7391be4b1faf8ff1a0d9f5ce87